A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Recruiting

Phase 1

RNDO-564 & PembrolizumabA Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Sponsor:

Rondo Therapeutics

Code:

NCT07218003

Conditions

Non Small Cell Lung Cancer

Cervical Cancer

Head and Neck Squamous Cell Cancer

Triple Negative Breast Cancer (TNBC)

Urothelial Carcinoma Bladder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RNDO-564

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-31. This information was provided to ClinicalTrials.gov by Rondo Therapeutics on 2025-10-24.